Bausch Health Publishes Pipeline Update For The Barclays Global Healthcare Conference
Bausch Health Companies Inc. (NYSE/TSX: BHC) presented an update at the Barclays Global Healthcare Conference on March 9, 2021. CEO Joseph C. Papa, along with other executives, detailed the company's current pipeline, particularly focusing on Salix and its rifaximin clinical development efforts. The presentation is accessible via the Investor Relations page on the Bausch Health website, allowing stakeholders to follow developments in this therapeutic area. Forward-looking statements indicate potential risks related to COVID-19 and project timelines, which might impact future performance.
- Update on Salix pipeline and rifaximin clinical development shared at a major healthcare conference.
- Increased visibility for investors through live webcast and accessible presentation materials.
- Risks associated with the COVID-19 pandemic could negatively impact project timelines and costs.
LAVAL, Quebec, March 9, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") has published a presentation that Joseph C. Papa, chairman and CEO, Sam Eldessouky, senior vice president and corporate controller, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to present at the Barclays Global Healthcare Conference today, March 9, 2021, at 2:25 p.m. ET.
The presentation, which provides an update on Bausch Health's current pipeline for Salix, including an update regarding its rifaximin clinical development efforts, is available on the Investor Relations page of the Bausch Health Companies Inc. website at: https://ir.bauschhealth.com/events-and-presentations/2021. A live webcast and audio archive of the event will also be available on the Investor Relations page of the Company's website.
About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.
Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words "expects," "intends," "plans," "should," "could," "would," "potential" or "target" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
Investor Contact: | Media Contact: |
Arthur Shannon | Lainie Keller |
(514) 856-3855 | (908) 927-1198 |
(877) 281-6642 (toll free) |
View original content to download multimedia:http://www.prnewswire.com/news-releases/bausch-health-publishes-pipeline-update-for-the-barclays-global-healthcare-conference-301243006.html
SOURCE Bausch Health Companies Inc.
FAQ
What was discussed in Bausch Health's presentation at the Barclays Global Healthcare Conference?
When did Bausch Health present at the Barclays Global Healthcare Conference?
Where can I find the presentation by Bausch Health regarding its pipeline updates?
What are the potential risks mentioned by Bausch Health in their latest update?
What is the significance of Bausch Health's update on its rifaximin clinical development?
